DelveInsightRecent news mentioning DelveInsight2026-08-04 — Lumbar Disc Herniation Market is Projected to Reach USD 7.2 Billion by 2036 as Novel Therapies and Minimally Invasive Treatments are Gaining Momentum | DelveInsight2026-08-03 — Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight2026-08-03 — Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight2026-07-30 — Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight2026-07-29 — Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight2026-07-28 — Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight2026-07-27 — Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight2026-07-23 — ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight2026-07-22 — CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight2026-07-22 — CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight2026-07-21 — Acute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsight2026-07-21 — Acute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsightAppears alongsideCAGRCARTL1AS1PLUMVOAALKADCPROTACNTDSee DelveInsight's full profile, network and analytical read on Beyond →